Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

ion in cash, cash equivalents, marketable securities and receivables due from our collaboration partner, which includes the $75 million of milestone payments that would be earned upon acceptance of the filing by the FDA.

The Company expects non-GAAP net income/loss to be near break-even for the full year ending December 31, 2013, which includes the reduction of expenses related to the assumption of Excess Amounts by Janssen.

"Over the past five months, we have been steadily and inexorably building the commercial personnel infrastructure that ensures Pharmacyclics has highly professional and competent Marketing, Medical Affairs, Drug Safety and Clinical Sales teams.  I am pleased to announce that we have completed the hiring process and we are now integrating our new team members into our culture and vision to ensure Pharmacyclics will be commercial-ready on a timely basis," said Bob Duggan, CEO & Chairman of Pharmacyclics. "We have entered into a very exciting chapter for the company and for our ibrutinib partner, Janssen, who has been a tremendous support in this process. Just 4 years ago we dosed our first patient with ibrutinib and since have explored its potential in most of the B-cell malignancies with Phase II and Phase III studies. Ibrutinib's success has been continuously evolving with three Breakthrough Therapy Designations announced earlier this year, two publications in the prestigious New England Journal of Medicine in June and the filing of our first NDA for ibrutinib with the Food and Drug Administration just a few weeks back. We are making very steady progress in our goal to advance science and drug development in the hopes of making a significant difference for the betterment of patients with serious, unmet healthcare needs."

Regulatory UpdateEarlier this month the Company submitted its first NDA to the FDA for the investigational oral BTK inhibitor, ibrutinib, for two relapsed/refractory
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
2. Pharmacyclics Reports First Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- In response to urgent requests from the Deputy Minister of ... , Direct Relief delivered two 10-bed medical tents to ... local health workers who contract Ebola while fighting the outbreak. ... was constructed for foreign health care workers who may contract ... Sierra Leonean health workers. With Sierra ...
(Date:12/22/2014)... MONMOUTH JUNCTION, N.J. , Dec. 22, 2014 ... immunotherapy company marketing its CytoSorb® blood purification technology ... cardiac surgery patients in 28 countries worldwide, today ... Di Russo , MD, FACS, as its Senior ... 2015. Dr. Di Russo ...
(Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has ... Glucose Market" report to their offering. ... insight focuses on the developments in the self-monitoring blood ... . Reimbursement analysis and the effects of competitive bidding ... 73 SMBG meters have been performed, based on the ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... a leader in the pharmaceutical treatment of breathing-control disorders, ... Thomas J. Dietz, Ph.D., as the company,s chairman.  Dr. ... a diversified financial-holdings and services company.   ... and a director of Pacific Growth Equities, LLC, a ...
... YORK, Oct. 26, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0158569/Medical-Imaging-Markets-Contrast-Agents.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging The ... are continuing to grow in significance as ...
Cached Medicine Technology:Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals 2Medical Imaging Markets: Contrast Agents 2Medical Imaging Markets: Contrast Agents 3Medical Imaging Markets: Contrast Agents 4Medical Imaging Markets: Contrast Agents 5Medical Imaging Markets: Contrast Agents 6
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding ... new selection of black one-shoulder cocktail dresses . In ... are available at discounted prices, up to 70% off. ... for three weeks only. You know, we have thousands of ... in our new items can visit our website for more ...
(Date:12/25/2014)... 2014 The short film “Color of Honor” ... honor of a true 9/11 hero, Welles Remy Crowther. It ... the 24 hours of Nuremberg International Short Film Festival and ... Actress, screenwriter and director Luciana Lagana plays the ... with her husband, Gregory Graham - Graham plays ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... In this News Digest:, Summary of a study being published ... finding that close relatives of women who carry mutations in ... genetic mutations -- do not have an increased risk of developing ... do not have such mutations. These results run counter to a ...
... , MONDAY, Oct. 31 (HealthDay News) -- People with ... disabled and less likely to return home than stroke patients ... looked at 702 people who had dementia at the time ... had a stroke. The stroke patients with pre-existing dementia ...
... - An unprecedented decade of economic demise and a population ... putting Michigan in a precarious spot: More aging residents needing ... Add in a steady decline in elderly support ratio ... and the situation becomes more dire. But with the help ...
... Men with prostate cancer are twice as likely to commit ... words may reduce this risk, reveals research at the Sahlgrenska ... a study at the University of Gothenburg,s Sahlgrenska Academy, researchers ... surgery for prostate cancer. The suicide rate in this group ...
... Oct. 31 (HealthDay News) --,The longer they live in the ... will develop health problems, a new study says. Researchers ... Examination Survey and discovered a dramatic increase in obesity, diabetes ... the United States for more than 20 years. Compared ...
... liberal in their advice to patients on alcohol consumption. ... while men who are heavy drinkers get to continue ... a thesis from the Sahlgrenska Academy at the University ... Gothenburg,s Sahlgrenska Academy have for the first time looked ...
Cached Medicine News:Health News:Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation 2Health News:Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation 3Health News:Dementia May Impede Stroke Recovery 2Health News:Michigan State University tackles health needs of an aging statewide population 2Health News:New findings could lower risk of suicide in men with prostate cancer 2Health News:Life in U.S. Not Always a Plus for Immigrants' Health 2Health News:Doctors' own alcohol consumption colors advice to patients 2
A highly precise stereotactic radiosurgery system for the treatment of intra-cranial lesions....
The Primus linear accelerator is a fully digital, technologically advanced radiation therapy treatment delivery system. It can be configured for delivery of routine, 3-D conformal or IMRT treatments....
... The cost-effective, proven and reliable ... rates for rapid patient treatment, fastest ... flatness - less than 500 milliseconds, ... highest beam stability, greatest number of ...
The Clinac 2100 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
Medicine Products: